Vertex Pharmaceuticals Inc. is on track to complete a BLA by the end of March seeking potential U.S. accelerated approval for povetacicept, its dual inhibitor of the BAFF and APRIL cytokines, to treat immunoglobulin A nephropathy (IgAN), following a successful phase III Rainier trial.
Frontier Biotechnologies Inc. has entered into an exclusive licensing agreement with GSK plc whereby GSK will obtain exclusive worldwide rights to develop, manufacture and commercialize two of Frontier’s small interfering RNA (siRNA) pipeline products.
Asahi Kasei Pharma Corp. has advanced its novel endothelin ETA receptor antagonist AK-1960 into phase I in Japan for the treatment of various refractory diseases, such as chronic kidney disease.
Changchun Genescience Pharmaceutical Co. Ltd. has received clearance from China’s National Medical Products Administration (NMPA) to start clinical trials with Gensci-136 for injection, a dual APRIL/BAFF antagonist in development for the treatment of immunoglobulin A nephropathy.
Shenzhen Salubris Pharmaceuticals Co. Ltd. has discovered dual antagonists of endothelin ETA receptor (EDNRA; ETRA) and angiotensin AT1 receptor (AGTR1; AT1). They are reported to be useful for the treatment of chronic kidney disease, IgA nephropathy, focal segmental glomerulosclerosis and hypertension.
Renal fibrosis originates from diverse etiologies, including diabetes, hypertension, glomerulonephritis and prolonged obstruction, which lead to persistent inflammation and altered repair processes that drive fibrogenesis. M2 macrophages, especially those expressing the macrophage mannose receptor (CD206), play a crucial role in driving fibrogenesis.
Scientists from Shenzhen Medical Academy of Research and Translation and the Southern Medical University have synthesized solute carrier family 22 member 12 (SLC22A12; URAT1) inhibitors. They are reported to be useful for the treatment of kidney injury, hyperuricemia and gout.
Paragonix Technologies Inc.’s Kidneyvault portable renal perfusion system managed to preserve and enable the reallocation of a donor kidney for more than 29 hours, despite prolonged ischemic time, multiple handoffs and two commercial flights. Throughout the period, the Kidneyvault maintained stable hypothermic preservation, preventing the organ from being discarded and allowing it to be transplanted into a patient.
Researchers from China hypothesized that Takeda G protein-coupled receptor 5 (TGR5), also known as G-protein coupled bile acid receptor 1, could have therapeutic potential in acute kidney injury by inhibiting ferroptosis.
A group at the University of Antwerp has patented ferroptosis inhibitors. They are reported to be useful for the treatment of acute renal failure, sepsis, ischemia-reperfusion injury and more.
RSS
